- 专利标题： OPTICALLY ACTIVE AZABICYCLIC DERIVATIVE
-
申请号： EP19854536.0申请日： 2019-08-26
-
公开(公告)号： EP3845533A1公开(公告)日： 2021-07-07
- 发明人: KAMIOKA, Seiji , BAN, Hitoshi , SHIMADA, Naoaki , HIROSE, Wataru , ARAKAWA, Akihiko , YAMAZAKI, Kazuto , HIRA, Kenjiro
- 申请人： Sumitomo Dainippon Pharma Co., Ltd.
- 申请人地址： JP Chuo-ku Osaka-shi Osaka 541-8524 6-8, Dosho-machi 2-chome
- 代理机构： Vossius & Partner Patentanwälte Rechtsanwälte mbB
- 优先权： JP2018158315 20180827
- 国际公布： WO2020045334 20200305
- 主分类号： C07D471/10
- IPC分类号： C07D471/10 ; A61K31/506 ; A61K45/00 ; A61P35/00 ; A61P35/02 ; A61P43/00 ; C07D487/10
摘要：
The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R 1 - R 4 are hydrogen atom or the like, and a - d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
信息查询
